PRESTO study has been presented at the 17th European Neuroendocrine Tumor Society ( ENETS ) Annual Conference.

PRESTO was a multi-national, multi-center, prospective, non-interventional, simulated-use study that enrolled 90 nurses with 2 years or more experience injecting with the Lanreotide ( Somatuline Depot ) syringe and/or the syringe for long-acting release Octreotide.
The primary objective of the PRESTO study was to assess nurse preference between the redesigned Somatuline Depot syringe and the syringe for long-acting release Octreotide after performing injections into injection pads.

The PRESTO study incorporated an anonymous, web-based questionnaire, where nurses reported their overall preference.
Virtually all participants ( 97.8% ) expressed a preference ( 85.6% strong, 12.2% slight ) for the redesigned Somatuline Depot syringe versus the Octreotide syringe.
Comparative safety and efficacy between Somatuline Depot and Octreotide were not evaluated in this study.

Indications for Somatuline Depot include the treatment of adult patients with unresectable, well- or moderately-differentiated, locally advanced or metastatic gastroenteropancreatic neuroendocrine tumors ( GEP-NETs ) to improve progression-free survival; treatment of adults with carcinoid syndrome; when used, it reduces the frequency of short-acting Somatostatin analog rescue therapy; and the long-term treatment of patients with acromegaly who have had an inadequate response to surgery and/or radiotherapy, or for whom surgery and/or radiotherapy is not an option.

A neuroendocrine tumor ( NET ) begins in the hormone-producing cells of the body’s neuroendocrine system, which is made of cells that are a combination of hormone-producing endocrine cells and nerve cells.
NETs are a group of uncommon tumors occurring in both men and women aged 50 to 60 years old although they can affect anyone of any age.
The three main areas where NETs are found in the body are the gastrointestinal tract, the pancreas and the lungs: a) Gastrointestinal NETs ( GEP-NETs ) are found in the gastrointestinal tract or digestive system and are the most common type of NETs; b) Pancreatic NETs ( pNETs ) are formed in the islet cells of the pancreas and include several uncommon types of NETs; c) Lung NETs are less common than other types, accounting for about one quarter of NETs.
The symptoms of NETs are often not distinct and difficult to identify, and average time from initial onset of symptoms to proper diagnosis can take more than 5 years.
Although NETs affect only a small percentage of the general population at any one time, the number of people being newly diagnosed with NETs overall is believed to be rising. This is mainly due to increased awareness of the condition and diagnostic testing.
NETs are now the fastest growing class of cancers worldwide, accounting for around 2% of all cancers at any time.

Acromegaly is an uncommon hormonal or endocrine disorder with slowly developing, but eventually distinct clinical symptoms.
In the U.S., approximately 3,500 new cases of acromegaly are diagnosed each year.
It is usually caused by having too much growth hormone in the body which, over time, results in some characteristic symptoms and signs, such as heavy or prominent facial features with a prominent jaw line and enlarged hands and feet. ( Xagena_2020 )

Source: Advances in Therapy, 2020

Xagena_Medicine_2020